Nicotine patches used for smoking cessation are safe in patients with coronary artery disease (CAD) and active stress-induced myocardial ischemia, according to the results of a randomized trial.
Nicotine patches used for smoking cessation are safe in patients with coronary artery disease (CAD) and active stress-induced myocardial ischemia, according to Monika J. Leja, MD.
Dr Leja and colleagues at The Methodist DeBakey Heart Center in Houston, Tex, studied 55 heavy smokers with >9% perfusion defect size on single photon emission computed tomography (SPECT), randomizing them to a 21-mg nicotine patch (n=28) or a placebo patch (n=27). The participants were not required to stop smoking to be included in the trial.
The safety of nicotine patches in patients with CAD who continue to smoke is uncertain because nicotine is known to increase heart rate and blood pressure, and may induce vasoconstriction, Dr Leja said.
As expected, nicotine levels increased significantly in the nicotine patch wearers but despite this increase, there was no significant change in the total or ischemic perfusion defect size from baseline in the active patch wearers, compared with the placebo patch wearers.
The total perfusion defect size did not change significantly in either group from baseline to Week 1. The total perfusion defect size decreased from 24.8% at baseline to 24.2% at Week 1 in the participants assigned to the nicotine patch, and from 21.1% at baseline to 18.6% at Week 1 in the participants assigned to the placebo patch.
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.